

Type*	Drug Name	Biologic Name Treatment (Indications*)	Biosimilar Name Treatment (Indications*)	Method of Administration
Anti-TNF	Adalimumab	Humira® Moderate to severe Crohn's disease (adult and pediatric), and ulcerative colitis (adult). Used for patients who have not responded well to conventional therapies, or who have lost response to other biologics.	N/A	SC
Anti-TNF	Infliximab	Remicade® Moderate to severe Crohn's disease (adult and pediatric), and fistulizing Crohn's (adult and pediatric). Moderate to severe ulcerative colitis (adult and pediatric). Patients who have not responded well to conventional therapies.	Inflectra® Moderate to severe Crohn's disease (adult), and fistulizing Crohn's. Moderate to severe ulcerative colitis (adult). Renflexis® Moderate to severe Crohn's disease (adult and pediatric), and fistulizing Crohn's. Moderate to severe ulcerative colitis (adult and pediatric).	IV
Anti-TNF	Golimumab	Simponi® Moderate to severe colitis (adults). Used when conventional medicines have not worked or cannot be tolerated, or in patients who have demonstrated steroid dependence.	N/A	SC
$\alpha 4 \beta 7$ Integrin Blocker	Vedolizumab	Entyvio® Moderate to severe Crohn's disease and colitis (adults). Used when conventional medicines have not worked well or cannot be tolerated, and in patients who have not had satisfactory response with infliximab.	N/A	IV
Antibody to the p40 subunit of IL-12 and IL-23	Ustekinumab	Stelara® Moderate to severe Crohn's disease (adults). Used when conventional therapies have not worked or cannot be tolerated, or in patients who have failed or were intolerant to treatment with one or more TNF blockers.	N/A	First dose by IV. Subsequent doses by SC.